Novavax, Inc.
Regulated industryPhysical productsSells to businessesTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $7.96
- 52-Week Range
- $6.20 – $13.39
- Market Cap
- $1.31B
- P/E (TTM)
- —
- EPS (TTM)
- -0.52
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- —
- PEG Ratio
- 1.32
- Return on Equity
- —
- Return on Assets
- -4.22%
- Gross Margin
- 5.30%
- Operating Margin
- -16.98%
- Profit Margin
- -18.64%
- Current Ratio
- 2.15
- Debt/Equity
- —
- Total Debt
- $295.26M
- Free Cash Flow
- $11.76M
- Revenue Growth
- -3.00%
- Earnings Growth
- —
- Enterprise Value
- $986.37M
Market Snapshot
About
Novavax, Inc. is a biotechnology company that develops next-generation vaccines for serious infectious diseases. The company gained prominence with its protein-based COVID-19 vaccine (Nuvaxovid) and is advancing candidates for influenza, COVID-flu combination vaccines, and other respiratory diseases. Novavax uses proprietary recombinant nanoparticle technology and Matrix-M adjuvant to enhance immune response.